Search…

    Saved articles

    You have not yet added any article to your bookmarks!

    Browse articles
    Select News Languages

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policies, and Terms of Service.

    AstraZeneca loses £20bn after drug trial failure

    2 weeks ago

    1

    0

    AstraZeneca's stock value dropped by over £20 billion following a failed trial for its Wainua drug, intended to treat heart disease. The drug did not meet its primary goal of reducing mortality when combined with standard care. This setback poses a significant challenge to AstraZeneca's future revenue targets and investor confidence in the company.
    Click here to Read more
    Prev Article
    Louise Thompson Visits Downing Street for Maternity Petition
    Next Article
    Midsummer Festival Held at Cloughbawn GAA Club

    Related Business Updates:

    Comments (0)

      Leave a Comment